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p53Spinocerebellar ataxia type 7 (SCA7) is one of the nine neurodegenerative disorders caused by expanded
polyglutamine (polyQ) domains. Common pathogenic mechanisms, including bioenergetics defects, have been
suggested for these so called polyQ diseases. However, the exact molecular mechanism(s) behind the metabolic
dysfunction is still unclear. In this study we identiﬁed a previously unreported mechanism, involving disruption
of p53 and NADPH oxidase 1 (NOX1) activity, by which the expanded SCA7 disease protein ATXN7 causes
metabolic dysregulation. The NOX1 protein is known to promote glycolytic activity, whereas the transcription
factor p53 inhibits this process and instead promotes mitochondrial respiration. In a stable inducible PC12
model of SCA7, p53 and mutant ATXN7 co-aggregated and the transcriptional activity of p53 was reduced,
resulting in a 50% decrease of key p53 target proteins, like AIF and TIGAR. In contrast, the expression of NOX1
was increased approximately 2 times in SCA7 cells. Together these alterations resulted in a decreased respiratory
capacity, an increased reliance on glycolysis for energy production and a subsequent 20% reduction of ATP in
SCA7 cells. Restoring p53 function, or suppressing NOX1 activity, both reversed the metabolic dysfunction and
amelioratedmutant ATXN7 toxicity. These results hence not only enhance the understanding of themechanisms
causing metabolic dysfunction in SCA7 disease, but also identify NOX1 as a novel potential therapeutic target in
SCA7 and possibly other polyQ diseases.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Spinocerebellar ataxia type 7 (SCA7) is one of the nine neurodegen-
erative disorders caused by expanded polyglutamine (polyQ) domains;
for review see [1]. These so called polyQ diseases are characterized by
intracellular aggregation of the expanded polyglutamine protein and
common toxic gain-of-function mechanisms have been suggested.
However, the exact toxicmechanism(s) is still unclear and the sequence
surrounding the polyQ tract is believed to modulate the toxicity and
contribute to the disease speciﬁc pattern of neuronal death in each dis-
ease [1–3]. In SCA7, the polyQ region is situated in ataxin-7 (ATXN7), a
protein implicated in regulation of cytoskeleton stability and STAGA-
(SPT3-TAF(II)31-GCN5L acetylase) mediated gene transcription [4–6].
Despite the widespread expression of ATXN7, mainly cerebellar,
brainstem and retinal neurons are affected in SCA7 [7].sport chain; HD, Hungtinton's
rylation; PolyQ, polyglutamine;
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om@neurochem.su.seOxidative stress, a situation where the levels of free radicals exceed
the capacity of the cell's endogenous anti-oxidant systems, has been
implicated in the pathology of polyglutamine diseases [1,8]. Recently,
we and others have linked enhanced production of reactive oxygen spe-
cies (ROS) by transmembrane NADPH oxidase (NOX) enzymes to the
oxidative stress and toxicity in polyQ disease [9–12]. Under normal
physiological conditions NOX enzymes generate low, local levels of su-
peroxide, thereby regulating a number of redox-sensitive intracellular
signaling molecules like phosphatases, transcription factors and ion
channels [8]. To date, seven NOX family members, NOX1-5 and
DUOX1-2, have been described and several of these are expressed in
neurons [8,13,14]. However, the physiological role of the different
NOX enzymes in the nervous system and how dys-regulation of these
enzymes occurs and contributes to neurodegeneration are still largely
unclear [8].
Besides oxidative stress, metabolic alterations and energy deﬁcits
have also been implicated in polyglutamine pathology [1,15]. Although
some energy can be produced in the cytoplasm by glycolysis, i.e. the
conversion of glucose into pyruvate, most ATP is generated when prod-
ucts of the tricarboxylic acid cycle (TCA), fatty acid and amino acid oxi-
dation are used by mitochondria during oxidative phosphorylation
(OxPhos) [16,17]. At the mitochondrial inner membrane, transfer of
electrons from NADH and succinate to oxygen via mitochondrial com-
plexes I–IV generates an electrochemical membrane gradient, which is
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complex V. In the presence of oxygen, most cells primarily convert the
pyruvate produced by glycolysis into acetyl-CoA, which then enters
the TCA and OxPhos. Abnormal glucose metabolism, as well as altered
TCA activity, has been reported in polyQ disease models and patients;
for review see [15,18]. At the cellular level, the major cause of the met-
abolic alterations and energy deﬁciency appears to bemitochondrial ab-
normalities [15,19–21]. In SCA7 patients, abnormal mitochondria
morphology, reduced electron transport chain activity, metabolic acido-
sis, as well as poor weight gain have been reported [19,22]. However,
the exactmechanisms behind themitochondrial damage andmetabolic
dysregulation in SCA7 and other polyQ diseases are still largely unclear.
The redox-sensitive transcription factor p53 plays a critical role in
maintaining the integrity of mitochondria and oxidative phosphoryla-
tion [23,24]. Key p53 target genes, important for mitochondrial OxPhos,
include AIF (apoptosis-inducing factor) and SCO2 (synthesis of cyto-
chrome c oxidase) [23,24]. In contrast to promoting OxPhos, the overall
effect of p53 on glycolysis is repressive [23,24]. This repressive effect isFig. 1.Mutant ATXN7 causes up-regulation of NOX1, but not NOX2 expression. (A) Analysis of
induced (−Dox) to express mutant GFP-tagged ATXN7 with 65 glutamines (ATXN7Q65-GFP
(B) Expression analysis of the 65 kDa NOX1 form in non-induced or FLQ65 cells induced to e
(C) Analysis of the 75 kDa NOX1 form, detected with an antibody from Sigma, in FLQ65 cells
FLQ10 cells induced to express wild-type GFP-tagged ATXN7 with 10 glutamines (ATXN7Q10-G
in FLQ10 cells grown as in B. Actin was used as loading control and for normalizations. All dat
p b 0.01, *** p b 0.001.mediated through negative regulation of glucose transporter (GLUT)
expression and p53-mediated induction of TIGAR (p53-inducible gly-
colysis and apoptosis regulator), which diverts glucose catabolism to
the pentose-phosphate pathway (PPP) [23,24].
In this study, we for the ﬁrst time show that the polyQ expanded
ATXN7 disrupts the metabolic regulatory function of p53 and results
in altered levels of AIF, TIGAR and GLUT1. In turn, this results in reduced
mitochondrial respiration, a higher dependence on glycolysis and re-
duced ATP levels.Moreover, we showed that theNOX1 activity is specif-
ically enhanced and is essential to sustain the metabolic dysregulation
and toxicity in SCA7 cells.
2. Materials and methods
2.1. Cell culture and plasmid transfections
The generation and characterization of Tet-off inducible FLQ10 and
FLQ65 PC12 cell lines, expressing C-terminal GFP tagged ATXN7 withNOX1 and 2 mRNA levels in control, i.e. non-induced FLQ65 (+Dox) cells, or FLQ65 cells
) for 12 days. Removal of doxycycline (Dox) from the media induces ATXN7 expression.
xpress mutant ATXN7 for the indicated number of days, using an antibody from Abcam.
grown and induced as in B. (D) Expression of the 75 kDa NOX1 form in non-induced or
FP). (E) NOX2 expression in FLQ65 cells grown and induced as in B. (F) NOX2 expression
a are shown as means ± SEM from at least three independent experiments. * p b 0.05, **
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scribed previously [9,25]. The expression of ATXN7 in these rat
neuronal-like cells is induced by the removal of doxycycline (Dox)
from the culture media. Cells were grown at 37 °C and 5% CO2, in
DMEM (Invitrogen) supplemented with 10% horse serum (Invitrogen),
5% Tet System Approved fetal bovine serum (PAA), 100 μg/ml G418
(Invitrogen), 100 units/ml penicillin G sodium, 100 μg/ml streptomycin
sulphate (Invitrogen), 100 μg/ml hygromycin (Invitrogen) and when
desired 1 μg/ml Dox (Sigma).
Human HeLa cells were grown at 37 °C and 5% CO2, in DMEM
(Invitrogen) supplemented with 10% fetal bovine serum (Promega)
and 100 units/ml penicillin G sodium. For HeLa transfections, plasmids
FLQ10, FLQ65, TrQ10 and TrQ65, expressing FLAG-tagged full-length
or truncated ATXN7 with 10 or 65 glutamines, respectively were used
[26]. Cells were transfected at 50–80% conﬂuency using Lipofectamine
2000 (Invitrogen), following the manufacturer's recommendations.Fig. 2.NOX1 inhibition reduces the ROS level and restores viability inmutant ATXN7 cells. (A) Ex
(−Dox) to express ATXN7Q65-GFP for 12 days and treated with control or NOX1 siRNA. (B)
(C) Total cellular ROS levels measured by DCHF-DA in FLQ65 cells grown and treated as in A.
grown as in A, but treated with 10 μMML171. (F) Toxicity measured by membrane leakage a
for 12 days while growing in media with or without 10 μMML171. All data are shown as mea
*** p b 0.001.2.2. NOX1 knock-down and treatments
Stable PC12 cell lines were transfected with either non-targeting
control small interfering si(RNA) or NOX1-speciﬁc siRNA from Santa
Cruz (sc-156079) or Ambion (ID no 55585). Non-induced or PC12
cells induced to express mutant ATXN7 for 9 days were grown in 6-
well plates and transfected at 50–80% conﬂuency using Lipofectamine
RNAiMAX transfection reagent (Invitrogen) and a ﬁnal siRNA concen-
tration of 50 nM according to the manufacturer's instructions.
When indicated, cells were treated with the following chemicals
all from Sigma Aldrich; rotenone (0–80 μM), 3-nitropropionic acid
(3-NP) (0–10 mM), antimycin A (0–200 nm), sodium azide (NaN3)
(0–70 mM), oligomycin (0–100 μM), vitamine E (α-tocopherol)
(1 μM), and apocynin (50 μM). Nutlin-3 (0–10 μM) and ML171
(0–10 μM) were purchased from VWR and EMD Millipore
respectively.pression analysis of the 75 kDaNOX1 form innon-induced (+Dox) or FLQ65 cells induced
Western blot analysis of the 65 kDa NOX1 form in FLQ65 cells grown and treated as in A.
(D) Total ROS in cells grown as in A, but treated with 1 μMML171. (E) Total ROS in cells
ssay, in non-induced (+Dox) or FLQ65 cells induced (−Dox) to express ATXN7Q65-GFP
ns ± SEM from three independent experiments. Dox: doxycycline. * p b 0.05, ** p b 0.01,
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Cell lysis, ﬁlter trap and western blotting were done as previously
described [9,27]. In brief, cells were lysed with RIPA buffer (Millipore)
and following centrifugation at 21,000 ×g the soluble fractions, i.e. the
supernatants, were collected. To obtain insoluble fractions, pellets
were resuspended in DNase I buffer and DNase I treated for 1 h. SDS
andDTTwere then added to a ﬁnal concentration of 2% and 100mM, re-
spectively. The protein concentrations in soluble and insoluble fractions
(before SDS and DTT addition) were measured using Bradford assay
(Bio-Rad). Soluble or insoluble fractionswere then analyzed bywestern
blot and ﬁlter trap analysis, respectively. Western blot and ﬁlter trap
assaymembraneswere blocked and then probedwith primary antibod-
ies at the following concentrations: Ataxin-7 1:700 [7,28], actin 1:500
(sc-1616, Santa Cruz), LDH 1:200 (sc-33781, Santa Cruz), NOX1
1:1000 (SAB4200097, Sigma), NOX1 1:500 (ab131088, Abcam), NOX2
1:200 (sc-74514, Santa Cruz) and p53 1:700 (SC-1313, Santa Cruz).
After secondary antibody incubation, the protein of interest was visual-
ized using SuperSignal West Pico or SuperSignal West extended dura-
tion substrates (Pierce) and the ChemiDoc XRS+ imaging system
(BioRad). The signal intensities of protein bands or dots were quantiﬁed
by Image Lab software (BioRad). For western blotting intensities were
normalized against actin or tubulin and the quota for the control sampleFig. 3. Expression of ATXN7Q65-GFP results in increased glycolytic activity. (A) Analysis of gl
12 days, respectively. (B) Glucose consumption in FLQ10 control cells induced to express wil
cells induced to express mutant ATXN7 for the indicated number of days. (D) Intracellular LD
for 0–12 days. (E) Analysis of LDH expression in FLQ65 cells grown and treated as in C. For we
three independent experiments.* p b 0.05, ** p b 0.01, *** p b 0.001.set to 100%. For ﬁlter trap analysis intensities were normalized against
the protein concentrations.
2.4. Toxicity measurements
Toxicity was measured by analysis of plasma membrane leakage
using the CytoTox-ONE™ assay from Promega as previously described
[9]. Brieﬂy, 50,000 induced or non-induced PC12 cells were seeded in
12-well cell culture plates 24 h before measurements. Following drug
treatment, 50 μl of cell culturemediawas transferred into 96well plates
and incubated at room temperature (RT) for 20 min. One hundred
microliters of CytoTox-ONE reagentwas added to each sample and ﬂuo-
rescence was measured using a Flex station II plate reader at an excita-
tion wavelength of 560 nm and an emission wavelength of 590 nm.
2.5. Determination of mitochondria membrane potential and oxygen
consumption
To evaluate the mitochondria membrane potential (Δψm), 20,000
induced or non-induced, treated or non-treated FLQ10 or FLQ65 PC12
cells were seeded in 96-well cell culture plates. Twenty-four hours
later the medium was removed, cells were washed and fresh medium
containing 10 nM of the ﬂuorescent probe tetramethylrhodamineucose consumption in FLQ65 cells induced to express mutant ATXN7 for 0, 1, 3, 6, 9, and
d-type ATXN7 for 0 or 12 days. (C) Analysis of hexokinase 2 (HK2) expression in FLQ65
H activity in FLQ10 and FLQ65 cells induced to express wild-type or mutant ATXN7-GFP
stern blots, actin was used for normalizations. All data are shown as means ± SEM from
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1 h at 37 °C in the dark. Fluorescence was thenmeasured at 550 nm ex-
citation and 580 nm emission wavelengths using a Flex station II plate
reader.
Tomeasure the oxygen consumption, FLQ65 cells non-induced or in-
duced for 12 days, were seeded into 96-well plates at 4 × 104 cells/well.
The following day oxygen consumptionwas performed according to the
manufacturer's protocol (600800, Cayman chemicals). Fluorescence
was measured at 380 nm excitation and 650 nm emission wavelengths
using a Flex station II plate reader. After the oxygen consumption assay,
the protein concentration in each well was determined using Lowry
assay (Bio-Rad) and the oxygen consumption was normalized against
the protein concentration. The value obtained from the untreated
non-induced sample was set to 100%.2.6. Measurement of intracellular LDH activity
Intracellular lactate dehydrogenase (LDH) activity was measured
using CytoTox-ONE reagent (Promega). Brieﬂy 50,000 seeded induced
or non-induced cellswere lysedwith 0.2% Triton X-100 (Sigma) and ex-
tracts were collected after centrifugation at 12,500 g for 10 min. Fifty
microliters of extracts was transferred to 96 well plates and incubated
at RT for 20 min before 100 μl of CytoTox-ONE reagent was added and
ﬂuorescence was measured using a ﬂex station II plate reader at an ex-
citation wavelength of 560 nm and an emission wavelength of 590 nm.Fig. 4.Mitochondrial respiratory chain impairment in mutant ATXN7 cells. (A) Mitochondrial m
type (Q10) or mutant (Q65) ATXN7 for 0, 6, 9, and 12 days, respectively. (B) Oxygen consump
ATXN7. (C) Toxicity in non-induced (+Dox) and FLQ65 cells induced (−Dox) to express ATXN
12h, (D) toxicity in cells grown as inB, but treatedwith the complex II inhibitor 3-NP, (E) toxicit
cells grown as in B, but treated with the complex IV inhibitor NaN3, and (G) toxicity in cells gro
FLQ10 or FLQ65 cells induced to express wild-type or mutant ATXN7 for 0, 6, 9, and 12 days, re
experiments.* p b 0.05, ** p b 0.01, *** p b 0.001.2.7. Glucose consumption and lactate level analysis
Glucose consumption and lactate levelswere analyzed using the glu-
cose assay and lactate assay kits from Sigma, following the instructions
from themanufacturer. For both assays, 1 × 106 induced or non-induced
FLQ10 or FLQ65 cells were seeded in 6 well plates and freshmedia were
added. Two days later the remaining glucose level in the media was de-
termined for each well and the glucose consumption was calculated as
the difference between the amounts of glucose in the fresh media and
the detected glucose levels after 48 hours.
For lactate level analysis, the cells were lysedwith lactate assay buff-
er. The extractswere centrifuged at 13,000×g for 10min and 50 μl of the
extract was taken into a 96 well plate and incubated at RT for 20 min.
Fifty microliters of reconstituted lactate assay reagent was then added
and incubated in the dark for 30 min at RT after which absorbance
was measured at 570 nm. Absorbance values were normalized with
the protein concentration.
2.8. Measurement of ATP
ATP was measured using the ATP assay kit (Sigma). Brieﬂy, 1 × 106
induced or non-induced FLQ10 or FLQ65 cells were seeded in 6 well
plates 48 h before the assay. On the day of analysis the cells were
washed two times in PBS and then lysedwith ATP release reagent. Hun-
dred microliters of lysate from each well was then transferred to an
opaque 96 well plate and 100 μl ATP assay mix working solution wasembrane potential measured by TMRE in FLQ10 or FLQ65 cells induced to express wild-
tion in non-induced (+Dox) and 12 days induced (−Dox) FLQ65 cells expressing mutant
7Q65-GFP for 6 days and treated with the mitochondrial complex I inhibitor rotenone for
y in cells grown as inB, but treatedwith the complex III inhibitor antimycinA, (F) toxicity in
wn as in B, but treated with the complex V inhibitor oligomycin. (H) The total ATP level in
spectively. Dox: doxycycline. All data are shown as means± SEM from three independent
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using a micro-plate luminometer (Promega). The obtained lumines-
cence values were normalized by protein concentration, and the value
obtained from non-induced sample was set to 100%.2.9. RNA puriﬁcation and reverse transcription–polymerase chain reaction
The mRNA expression of NOX1, NOX2, GLUT1, AIF, and TIGAR was
evaluated by the semi-quantitative RT-PCR method. RNA from non-
induced and 12-day induced FLQ65 cells was puriﬁed using the GeneJet
RNA puriﬁcation kit (#KO731, Thermo Scientiﬁc). Two thousand nano-
grams of total RNA was used for RT-PCR using RevertAid H minus First
strand cDNA synthesis kit (#K1631, Thermo Scientiﬁc). Transcribed
mRNAs in each sample were ampliﬁed using validated rat primers
from Qiagen or Santa Cruz for rat ACTIN, GAPDH, NOX1, NOX2, NOX4,
GLUT1, AIF, and TIGAR and quantiﬁed at individual cycle number for
each transcript using a ChemiDoc XRS + imaging system (Bio-Rad)
and the Image Lab software (Bio-Rad). Actin mRNA levels were used
for normalizations.2.10. Statistical analysis
Statistical analyses were done by one-way ANOVA followed by
Tukey's post-hoc test using Prism graph pad 5.0.Fig. 5. NOX1 inhibition or ROS scavenging reverses the mutant ATXN7 induced metabolic shi
express mutant ATXN7 for 12 days and treated with control or NOX1 siRNA. (B) Glucose con
(Vit E). (C) Lactate levels in FLQ65 cells grown and treated as in B. (D) LDH expression in FLQ
grown and treated with Vit E as in B. (F) Mitochondria membrane potential in FLQ65 cells gro
(+Dox) or FLQ65 cells induced (−Dox) to express mutant ATXN7 for 12 days while grow
quantiﬁcations in western blots. Data are shown as means ± SEM from three independent exp3. Results
3.1. NOX1 expression and activity are increased in mutant ATXN7 cells
We have previously shown that expression of mutant ATXN7
(ATXN7Q65-GFP) in a stable inducible SCA7 PC12 cell model (FLQ65)
results in increased ROSproduction byNADPHoxidases, oxidative stress
and toxicity [9]. To determinewhich speciﬁc NOXmember(s) that is in-
volved in the mutant ATXN7 induced toxicity, we analyzed the expres-
sion of different NOX members in our SCA7 model. The results showed
that both NOX1 andNOX2 are expressed in PC12 cells (Fig. 1). However,
upon induction ofmutant ATXN7 expression, by the removal of doxycy-
cline (Dox) from themedia, theNOX1mRNA levelwas up-regulated ap-
proximately 6 times, whereas the NOX2 level remained unchanged
(Fig. 1A). Analysis of NOX1 protein levels with western blot resulted in
detection of two different sized NOX1 protein forms, one of around
65 kDa, primarily detected by an antibody from Abcam (Fig. 1B), and a
75 kDa form, primarily detected using an antibody from Sigma
(Fig. 1C). Both NOX1 forms were increased, between 1.5 and 10 times,
upon induction of mutant ATXN7 (Fig. 1B–C), and the increase of both
forms was speciﬁcally down-regulated by siRNA directed against rat
NOX1 (Fig. 2A–B). In contrast, induction of mutant ATXN7 had no effect
on the level of NOX2 protein (Fig. 1E). Furthermore, induction of ATXN7
with a non-disease causing repeat of 10 glutamines (ATXN7Q10-GFP) in
FLQ10 control cells did not alter either the NOX1 or NOX2 expression
(Fig. 1D and F).ft. (A) Glucose consumption in non-induced (+Dox) or FLQ65 cells induced (−Dox) to
sumption in cells grown as in A, but treated with 1 μM of the ROS scavenger vitamin E
65 cells grown and treated with NOX1 siRNA as in A. (E) LDH expression in FLQ65 cells
wn and treated with Vit E as in B. (F) Mitochondria membrane potential in non-induced
ing in media with or without 50 μM Apocynin. Actin was used as loading control for
eriments. Dox: doxycycline. * p b 0.05, ** p b 0.01, *** p b 0.001.
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the increased ROS generation in SCA7 cells, wemeasured the ROS levels
in FLQ65 cells following NOX1 knock-down or inhibition. As expected,
NOX1 siRNA, as well as treatment with the NOX1 inhibitor ML171,
which has a greater than 30-fold selectivity for NOX1 over other NOX
isoforms [29], completely reversed the ~25% ROS increase in
ATXN7Q65-GFP expressing cells (Fig. 2C–E). Furthermore, inhibition
of NOX1 also ameliorated themutant ATXN7 toxicity (Fig. 2F). Taken to-
gether, these results suggest that mutant ATXN7 causes increased ROS
levels and oxidative stress by up-regulation and activation of the
NOX1 enzyme.
3.2. ATXN7Q65-GFP expression results in metabolic dysregulation and
reduced ATP levels
NOX1 activity was recently linked to regulation of the balance be-
tween glycolysis andmitochondrial respiration [30–32]. Next,we there-
fore investigated the glycolytic activity by measuring the glucose
consumption, the expression level of hexokinase 2 (HK2), as well as
the LDH activity and expression in SCA7 cells. A clear gradual increase
in glucose consumption (Fig. 3A), HK2 expression (Fig. 3C), intracellular
LDH activity (Fig. 3D) and LDH expression (Fig. 3E) could be detectedFig. 6. The p53 transcriptional regulation of metabolic genes is altered in SCA7 cells. (A). Analys
or ATXN7Q65-GFP for the indicated number of days. Aggregated ATXN7 and p53 were collect
GLUT1 mRNA levels in non-induced (+Dox) or FLQ65 cells induced (−Dox) to express mutan
blot analysis of TIGAR, AIF and GLUT1 protein levels in FLQ65 cells induced to express ATXN7Q6
(E). Quantiﬁcation of the AIF expression level. (F). Quantiﬁcation of the GLUT1 expression level.
are shown as means ± SEM from three independent experiments. * p b 0.05, ** p b 0.01, *** pfrom six days onwards after induction of mutant ATXN7 in FLQ65
cells. Twelve days after induction an approximate 30–40% increase in
glucose consumption and a 30–50% increase in HK2, as well as LDH ex-
pression and activity, could be observed. In addition, a 25% increase in
the lactate level could be observed in mutant ATXN7 cells (Fig. 5C). In
contrast, induction of wild-type ATXN7 in FLQ10 control cells had no ef-
fect on glucose consumption, HK2 or LDH (Fig. 3B, D and data not
shown).
To determine the status of the electron transport chain (ETC.) and
mitochondrial respiration in SCA7 cells, we next analyzed the mito-
chondria membrane potential (Δψm) and the oxygen consumption. In
FLQ65 cells induced to express mutant ATXN7 the Δψmwas gradually
decreased from day 9 onwards (Fig. 4A), whereas induction of wild-
type ATXN7 had no effect on the Δψm (Fig. 4A). Oxygen consumption
was also signiﬁcantly reduced by approximately 20% in mutant ATXN7
expressing cells (Fig. 4B). To further conﬁrm the negative effect of mu-
tant ATXN7 on mitochondrial ETC. function we also, as previously done
in HD polyglutamine disease models, assessed the sensitivity of control
and induced FLQ65 cells to inhibitors of mitochondria complexes I, II, III,
IV and V [20,33]. The experiments were performed six days after induc-
tion, when expression of mutant ATXN7 by itself has not yet induced
toxicity (Fig. 4C–G). However, at this early time-point treatment withis of p53 and ATXN7 co-aggregation in FLQ10 or FLQ65 induced to express ATXN7Q10-GFP
ed and analyzed by cell fractionation and ﬁlter trap assay. (B) Analysis of TIGAR, AIF and
t ATXN7 for 12 days. The mRNA levels of actin were used for normalization. (C). Western
5-GFP for the indicated number of days. (D). Quantiﬁcation of the TIGAR expression level.
Forwestern blot quantiﬁcations, actinwas used for normalizations. Dox: doxycycline. Data
b 0.001.
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mutant ATXN7 expressing cells, compared to non-induced control cells
(Fig. 4C–G), indicating that the electron transport chain is compromised
by mutant ATXN7. Interestingly, mutant ATXN7 did not sensitize cells
towards complex IV inhibition (Fig. 4F).
To analyzewhether the observedmetabolic changes had an effect on
the energy level in SCA7 cells, we next analyzed the ATP levels in non-
induced and induced FLQ10 and FLQ65 cells. A gradual decrease of the
ATP level was observed upon induction of mutant ATXN7 in FLQ65
cells, and twelve days after induction the ATP level was decreased by
20% (Fig. 4H). In contrast, no change in the ATP levels could be observed
in FLQ10 cells expressing wild-type ATXN7 at any time point (Fig. 4H).
3.3. NOX inhibition or ROS scavenging reverses the mutant ATXN7 induced
metabolic dysregulation
To establish if the increased NOX1 activity in mutant ATXN7 cells is
required for promoting the observedmetabolic dysfunction,we next in-
vestigated whether the metabolic status could be restored by NOX1
knock-down or scavenging of NOX1 produced ROS. Indeed, the increase
in glucose consumption (Fig. 5A–B), lactate (Fig. 5C) and LDH levels
(Fig. 5D–E), as well as the decrease in mitochondrial membraneFig. 7. Nutlin-3 treatment restores the p53-mediated regulation of metabolic proteins. (A). W
12 days induced (−Dox) FLQ65 cells grown in media with or without nutlin-3 (0–10 μM). (B
level. (D). Quantiﬁcation of the AIF expression level. (E). Quantiﬁcation of the GLUT1 expre
means ± SEM from three independent experiments. Dox: doxycycline. * p b 0.05, ** p b 0.01, *potential (Fig. 5F–G) could all be reversed by NOX1 knock-down or
ROS scavenging.
To verify that the metabolic dysfunction induced by mutant ATXN7
is not speciﬁc to the inducible SCA7 PC12 cell model, we transiently
transfected human HeLa cells with ATXN7 expression constructs and
analyzed the NOX1 level, as well as the metabolic status 72 h later.
Also in this SCA7 model, expression of mutant full-length (FLQ65) or
truncated (TrQ65) ATXN7 resulted in a small approximately 10% in-
crease in NOX1 expression, compared to control cells expressing wild-
type ATXN7 (Supplementary Fig. S1). Moreover, the small increase in
NOX1 was associated with increased glycolytic activity, evident by for
instance an approximate 20% increase in glucose consumption and
LDH expression in HeLa cells (Supplementary Fig. S1).
3.4. Altered p53 function contributes to the metabolic dysfunction
The p53 protein is a key regulator of cellular metabolism. Using the
same stable inducible SCA7 model as in this study, we have previously
shown that p53 co-aggregates with mutant ATXN7 and that this re-
duces the soluble p53 level and transcriptional activity [27]. Consistent
with this, we could again in induced FLQ65 cells detect p53 in the insol-
uble cell fractions containing mutant ATXN7 aggregates; see Fig. 6A.estern blot analysis of p53, TIGAR, AIF and GLUT1 expression in non-induced (+Dox) or
). Quantiﬁcation of the p53 expression level. (C). Quantiﬁcation of the TIGAR expression
ssion level. Actin was used for normalization prior to quantiﬁcation. Data are shown as
** p b 0.001.
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again detected in SCA7 cells; see Fig. 7A–B. In contrast, no detection of
p53 in the insoluble fraction or change of soluble p53 levels, could be
observed in FLQ10 control cells induced to express wild-type ATXN7
(Fig. 6A and data not shown).
To investigate whether the altered p53 level contributes to themet-
abolic dysfunction in SCA7, we analyzed the expression of some key
metabolic genes/proteins, positively (TIGAR and AIF) or negatively
(GLUT1), regulated by p53 on the transcriptional level. Consistent
with the reduced soluble p53 levels, we could detect a signiﬁcant 30%
decrease of TIGAR and AIF mRNA, as well as a small, but non-
signiﬁcant, increase in GLUT1 mRNA in mutant ATXN7 cells (Fig. 6B).
In agreement with the mRNA results, the protein levels of TIGAR and
AIF were gradually decreased, while a gradual increase in GLUT1 was
observed following induction of mutant ATXN7 in FLQ65 cells
(Fig. 6C–F). In fact, twelve days after induction TIGAR, AIF and GLUT1
protein levels were all changed by approximately 50%.
To further reassert the role of p53 dysfunction, we next investigated
whether increasing the p53 levels could reverse the mutant ATXN7 in-
duced metabolic alterations. Indeed, nutlin-3 treatment, which in-
creased the p53 level by approximately 50% (Fig. 7A–B), not only
restored the expression levels of TIGAR, AIF and GLUT1 (Fig. 7A–E),
but also reversed the metabolic dysregulation. This was evident by for
instance the restoration of glucose consumption (Fig. 8A) and the LDH
expression level (Fig. 8B–D). Interestingly, enhancing p53 levels also
prevented the up-regulation of NOX1 expression in mutant ATXN7
cells (Fig. 8B–C).
4. Discussion
Metabolic dysfunction has been implicated in the pathology of SCA7
[1,19,22]. However, the exact molecular mechanism(s) underlying
this pathological change have not been established. In this study, we
therefore set out to investigate how mutant ATXN7 affects cellular
metabolism and found that the mutant protein caused mitochondrialFig. 8. Enhancement of the p53 level reverses themetabolic shift inmutant ATXN7 cells. (A) Glu
in media with or without nutlin-3 (0–10 μM). (B) Western blot analysis of NOX1 and LDH exp
expression. (D)Quantiﬁcation of the LDH expression. Actinwas used for normalization prior to
experiments. * p b 0.05, ** p b 0.01, *** p b 0.001.dysfunction, metabolic imbalance and reduced ATP production by
disrupting p53 and NOX1 activities.
The p53 transcription factor is a major regulator of cellular metabo-
lism. In SCA7 cells, we could show that p53 co-aggregates with mutant
ATXN7 and the soluble p53 levels and the p53 transcriptional activity is
thus reduced (Figs. 6–7). In turn, this resulted in a more than 50% de-
crease in the level of some key p53-regulated metabolic proteins like
AIF. AIF is essential for the integrity of the mitochondrial ETC. and AIF
knock-out mice show mitochondrial abnormalities and reduced respi-
ratory capacity; for review see [34]. Consistent with this, we found
that SCA7 cells had reduced ETC. integrity, mitochondrial membrane
potential and oxygen consumption (Fig. 4). Loss of AIF function might
hence be a key contributor to themitochondrial abnormalities observed
in SCA7 [19]. This is further supported by the fact that loss of AIF inmice
results in neurodegeneration and death of primarily cerebellar and ret-
inal neurons, the neuronal types mostly affected in SCA7 disease [34].
In addition to promotingmitochondrial respiration, p53 also inhibits
glycolysis under normal conditions. This is achieved through induction
of TIGAR and negative regulation of GLUT expression [23,24]. In SCA7
cells, the reduced p53 function resulted in 50% lower TIGAR and 40%
higher GLUT1 expression and thus an increased glycolytic activity
(Fig. 6). This was evident by an increased glucose consumption, HK2
and LDH expression, as well as LDH activity in SCA7 cells (Fig. 3). In-
creasing the p53 activity in SCA7 cells, not only restored the expression
of AIF, TIGAR and GLUT1, but also reversed the metabolic disruption
(Figs. 7–8). Taken together, our results show that themutant ATXN7 in-
duced p53 dysregulation causes a metabolic imbalance with decreased
respiratory capacity and an increased reliance on glycolysis for energy
production. As a consequence the ATP levels were reduced by 20% in
SCA7 cells (Fig. 4).
Enhanced activation of the NOX1 enzymewas recently shown to be
critical in supporting elevated glycolysis in cancer cells suffering from
mitochondrial respiratory defect [30]. In agreement with this, we
found that the reduced respiration in SCA7 cells was coupledwith a sig-
niﬁcant up-regulation of NOX1 on both the mRNA and protein levelcose consumption in non-induced (+Dox) or 12 days induced (−Dox) FLQ65 cells grown
ression in cells grown and treated as in A. (C) Quantiﬁcation of the 75 kDa NOX1 protein
quantiﬁcation. Dox: doxycycline. Data are shown asmeans± SEM from three independent
Fig. 9. Proposed model of mutant ATXN7 induced metabolic dysfunction and oxidative stress. p53-mutant ATXN7 co-aggregation and NOX1-mediated inactivation of p53 results in
reduced p53-mediated transcriptional regulation of essential metabolic proteins, including TIGAR, AIF and GLUT1. In turn this results in reduced mitochondrial function and ATP
production. NOX1 activity is induced in response to the increased dependence on glycolysis and potentially also through decreased negative regulation by p53. The enhanced ROS
production from NOX1 results in oxidative stress and further reduction of p53 function.
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was required for the metabolic dysregulation in SCA7 cells, as knock-
down or inhibition of NOX1 reversed the metabolic phenotype
(Fig. 2). Interestingly, two forms of NOX1, one of the predicted 65 kDa
size and another larger form of ~75 kDa, were detected and found to
be increased in SCA7 cells. The 75 kDa NOX1 form has previously been
reported in rat cells and suggested to be a post-translationally modiﬁed
form of NOX1 [35].
How NOX1 activity supports the metabolic dysregulation in SCA7
cells is still largely unclear. However, NAD+ generated by NOX1 during
ROS production could activate SIRT1, resulting in enhanced p53
deacetylation and reduced p53 transcriptional activity [36]. Further-
more, p53 contain redox sensitive thiol groupswhich could bemodiﬁed
by ROS generated from NOX1 [37,38]. In fact, the metabolic dysregula-
tion in SCA7 cells could be blocked, not only by NOX1 knock-down,
but also by ROS scavenging, suggesting that the NOX1 generated ROS
is indeed essential for the metabolic dysregulation (Fig. 5). It is thus
tempting to speculate that the increased NOX1 activity could result in
p53 inactivation, which together with the p53-ATXN7 co-aggregation,
synergistically would cause a reduction in soluble transcriptional active
p53 able to regulate AIF, TIGAR and GLUT1 expression. Interestingly, we
could also observe that upon increasing the p53 activity in SCA7 cells,
NOX1 expression was normalized (Fig. 8), suggesting that p53 might
in turn negatively control the NOX1 expression. Taken together, this
could thus create a feed-forward loop (Fig. 9), where p53-ATXN7 co-
aggregation and NOX1-mediated p53 inactivation result in reduced
p53 transcriptional activity, metabolic dysregulation and further NOX1
activity, as well as oxidative stress. In fact, we have shown that breaking
this proposed cycle, through blockage of p53-ATXN7 co-aggregation
[27], increasingp53 levels (Figs. 7–8), aswell as inhibitingNOX1 activity
or ROS scavenging (Fig. 5) ameliorate the mutant ATXN7 induced
dysfunction.
In conclusion, we have identiﬁed a novel mechanism in which mu-
tant ATXN7 by disrupting p53 function and inducing NOX1 activity re-
sults in metabolic dysregulation, reduced ATP levels, oxidative stress
and toxicity. Our results not only enhance the understanding of mecha-
nisms causing metabolic dysfunction and toxicity in SCA7 disease, but
also identify NOX1 as a novel potential therapeutic target in SCA7 and
possibly other polyQ diseases.
Supplementary data to this article can be found online at http://dx.
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